The accelerating incidence and dismal mortality of hepatocellular carcinoma (HCC) (5-yr survival <12%) highlight the urgent need to improve prediction and prevention of this deadly neoplasm. HCC develops from advanced fibrosis due to hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol, or non-alcoholic fatty liver disease (NAFLD). A 186-gene prognostic signature in stromal cirrhotic liver, previously identified and validated in HCV-related cirrhosis, holds promise to identify patients with highest HCC risk and provide clues to HCC prevention targets. It remains unknown whether this signature is also prognostic for other HCC etiologies. Moreover, the signature has not yet been adapted as a clinically applicable test. Our long-term goal is to develop clinically applicable prognostic biomarkers for the global cirrhosis population caused by variety of etiologies to enable more effective, personalized HCC surveillance and prevention. The objective here is to establish prognostic relevance of the 186-gene signature in the non-HCV etiologies, identify etiology-specific molecular prognostic factors, implement and refine the signature as a clinically applicable assay, and develop genomic database for prognostic biomarker assessment. Our central hypotheses are that the 186-gene signature is universally prognostic irrespective of etiology, and that there are also complementary, etiology-specific prognostic indicators. We will test these hypotheses and address the unmet need by the following interrelated Specific Aims: 1. Establish a gene signature of HCC risk and poor prognosis in patients with non-HCV etiologies of advanced liver disease. We will perform whole-genome expression profiling of stromal cirrhotic liver tissues (905 cirrhosis and 1025 HCC cases affected by HBV, HCV, alcohol, or NAFLD), and validate predictive capability for HCC development as well as cirrhosis progression and death. Etiology-specific prognostic gene signatures will also be identified using the whole-genome datasets. 2. Develop a clinically applicable prognostic test using gene signature that defines HCC risk. We will implement the signature in the digital transcript counting technology specifically designed for clinical lab (nCounter assay, NanoString), and optimize experimental and analytical methods. Transcriptome sequencing-based prediction will also be evaluated as a potential future platform of a clinical test. 3. Develop a web resource for in silico prognostic biomarker assessment for cirrhosis and HCC. Our new and existing datasets, representing a global cirrhosis patient population, will be assembled as a public database that enables quick and easy clinical utility assessment of a user's prognostic molecular signatures.

Public Health Relevance

Liver cirrhosis and cancer are extremely prevalent and lethal diseases, in which key prognostic drivers are still elusive. We propose to establish prognostic biomarkers and generate a panel of genomic datasets comprehensively representing the patient population with liver cirrhosis and cancer worldwide. These data and resources will enable more precise, individualized patient management and contribute to significant improvement in liver cancer's dismal prognosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK099558-02
Application #
8698413
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Sherker, Averell H
Project Start
2013-07-15
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$696,850
Indirect Cost
$285,729
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Kim, Rosa S; Hasegawa, Daisuke; Goossens, Nicolas et al. (2016) The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. Sci Rep 6:39342
Jiao, Jingjing; Ooka, Kohtaro; Fey, Holger et al. (2016) Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice. J Hepatol 65:344-53
Verrier, Eloi R; Colpitts, Che C; Bach, Charlotte et al. (2016) Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Cell Rep 17:1357-1368
Bollard, Julien; Miguela, Verónica; Ruiz de Galarreta, Marina et al. (2016) Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut :
Goossens, Nicolas; Hoshida, Yujin; Song, Won Min et al. (2016) Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clin Gastroenterol Hepatol 14:1619-1628
Goossens, Nicolas; Hoshida, Yujin (2016) Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases? Gastroenterology 150:1710-7
Tan, Poh Seng; Nakagawa, Shigeki; Goossens, Nicolas et al. (2016) Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int 36:108-18
Bandiera, Simonetta; Billie Bian, C; Hoshida, Yujin et al. (2016) Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol 20:99-105
Zhang, Chi; Hoshida, Yujin; Sadler, Kirsten C (2016) Comparative Epigenomic Profiling of the DNA Methylome in Mouse and Zebrafish Uncovers High Interspecies Divergence. Front Genet 7:110
Schmidt, Benjamin; Wei, Lan; DePeralta, Danielle K et al. (2016) Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. Int J Cancer 138:1494-505

Showing the most recent 10 out of 53 publications